Thomas Pfisterer files SEC Form 4 disclosures for ADC Therapeutics SA. They have made 1 open-market trade across 1 company since 2024, most recently 2025-05-15.
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| ADCT | 173,899 | $189K |
Shares reported on the most recent Form 4, priced at the 2025-05-19 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ADCT | SELL | 2024-06-17 | 2024-06-18 | $2.89 | $4K | +38.3% | +38.0% | +15.8% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.